Everolimus Tablet, For Suspension
Product Images NDC 70954-773

Product Visual Gallery

This gallery contains 40 technical images submitted to the FDA as part of the official labeling for Everolimus (NDC 70954-773). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ani Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Blister-2mg (Blister 2mg)

Packaging label for Everolimus Tablet for Oral Suspension, 2 mg strength, distributed by ANI Pharmaceuticals, Inc. The label includes storage instructions at 20°C to 25°C (68°F to 77°F), protection from light and moisture, an NDC number 70954-773-10, and space for lot number and expiration date. The label also shows the dosage form as a tablet for suspension and specifies that it is for prescription use only. A separate label displays "Empty Cavity" with the ANI Pharmaceuticals logo and additional manufacturing codes.*

FDA Label Image

Blister-3mg (Blister 3mg)

Label sheet for Everolimus Tablet for Oral Suspension 3 mg, featuring multiple identical labels each including storage instructions (20°C to 25°C), handling precautions, and distributor information for ANI Pharmaceuticals, Inc., Baudette, MN. The sheet also shows a smaller label for an empty cavity with the ANI Pharmaceuticals logo and product lot and expiration date placeholders.*

FDA Label Image

Blister-5mg (Blister 5mg)

The image shows a packaging label for Everolimus Tablet for Oral Suspension, 5 mg strength, by ANI Pharmaceuticals, Inc. The label includes storage instructions (store at 20°C-25°C, protect from light and moisture), prescription-only status (Rx only), NDC 70954-775-10, and distributor information in Baudette, MN. The layout features multiple identical sections with lot and expiration date placeholders, a barcode, and the ANI Pharmaceuticals logo with a note of expiration 09/2025.*

FDA Label Image

Carton-2mg (Carton 2mg)

Everolimus Tablets for Oral Suspension 2 mg carton label by ANI Pharmaceuticals, Inc. The label states the tablets must be dispersed in water and not swallowed whole, chewed, or crushed. Each carton contains 28 tablets in 4 blister cards of 7 tablets each. Additional label text includes storage instructions and a note that it is Rx only.*

FDA Label Image

Carton-3mg (Carton 3mg)

Everolimus Tablets for Oral Suspension 3 mg carton label showing dosage form as tablets for suspension, each tablet containing 3 mg everolimus. The package contains 28 tablets in four blister cards. Labeler is ANI Pharmaceuticals, Inc. Instructions specify tablets must be dispersed in water and not swallowed whole, chewed, or crushed. Storage and usage information is also included.*

FDA Label Image

Carton-5mg (Carton 5mg)

The packaging label for Everolimus Tablets for Oral Suspension, 5 mg strength, by ANI Pharmaceuticals, Inc. The label specifies that the tablets must be dispersed in water and not swallowed whole, chewed, or crushed. Each carton contains 28 tablets distributed in 4 blister cards with 7 tablets each. The label includes storage instructions and a caution to keep medication out of reach of children.*

FDA Label Image

Figure A (Figure A)

Illustration of a syringe with labeled parts including the tip, volume indicators on the barrel, the barrel itself, and the plunger. This diagram shows the components of a syringe typically used for oral suspension medication administration.*

FDA Label Image

Figure-aa (Figure Aa)

An instructional illustration showing a hand stirring a substance in a small clear container using a spoon. The image likely demonstrates preparation steps for Everolimus oral suspension tablets by ANI Pharmaceuticals, Inc.*

FDA Label Image

Figure-b (Figure B)

An instructional illustration depicting two hands being washed or rinsed under running water from a faucet, with soap lather visible between the hands.*

FDA Label Image

Figure-bb (Figure Bb)

An illustration showing a person drinking from a glass, demonstrating oral administration of a medication. This image is likely instructional for the oral suspension dosage form of Everolimus tablets by ANI Pharmaceuticals, Inc.*

FDA Label Image

Figure-c (Figure C)

An instructional illustration showing a person pulling on a disposable glove, demonstrating proper glove wearing technique likely related to handling the Everolimus tablet for suspension.*

FDA Label Image

Figure-cc (Figure Cc)

An instructional black-and-white illustration showing a hand stirring a liquid in a transparent cup with a spoon, likely demonstrating the preparation or mixing of a tablet for oral suspension.*

FDA Label Image

Figure-d (Figure D)

An instructional illustration showing two oral syringes, one laying horizontally with visible volume markings up to 10 mL, and the other syringe shown from a different angle. The syringes are used for measuring and administering liquid medication, such as Everolimus tablets for suspension oral dosing.*

FDA Label Image

Figure-dd (Figure Dd)

An instructional illustration showing a person drinking from a glass, demonstrating how to take an oral medication or suspension by mouth.*

FDA Label Image

Figure-e (Figure E)

Illustration showing hands using scissors to cut a blister card containing tablets, demonstrating how to separate individual doses from the strip.*

FDA Label Image

Figure-ee (Figure Ee)

An instructional illustration showing a water faucet dripping water, a glass, and a spoon on a table surface. The image suggests preparing a suspension dose, likely to be mixed with water before administration.*

FDA Label Image

Figure-f (Figure F)

An instructional illustration showing a hand holding an open tube or vial while another hand places a tablet into the opening, indicating preparation of the Everolimus tablet for suspension before oral administration.*

FDA Label Image

Figure-g (Figure G)

An instructional illustration showing hands assembling or preparing an oral suspension tablet using a dropper and a container, likely demonstrating the method of mixing or administering Everolimus tablets for suspension.*

FDA Label Image

Figure-h (Figure H)

An instructional illustration depicting a hand holding a syringe with the thumb pushing the plunger, indicated by an arrow pointing in the direction of the push. The syringe barrel features measurement markings, presumably for dosing.*

FDA Label Image

Figure-i (Figure I)

An instructional illustration showing a hand holding an oral suspension tablet dispenser of Everolimus being submerged and dissolved in a glass of water. A close-up inset highlights the tablet dissolving at the bottom of the glass, demonstrating preparation steps for oral administration.*

FDA Label Image

Figure-j (Figure J)

An instructional illustration showing how to use an oral syringe to extract medication from a bottle, emphasizing the removal of air bubbles from the syringe by tapping and expelling air before administration.*

FDA Label Image

Figure-k (Figure K)

Illustration showing a dosing syringe placed inside a glass, accompanied by a clock indicating a 3-minute wait time. The image likely relates to the preparation or administration instructions for Everolimus oral suspension tablets by ANI Pharmaceuticals, Inc.*

FDA Label Image

Figure-l (Figure L)

Illustration showing hands holding two syringes, with an arrow indicating to invert and mix them 5 times. This instructional image likely relates to preparation or mixing of a liquid dosage form for oral administration.*

FDA Label Image

Figure-m (Figure M)

An instructional illustration showing a hand holding a syringe-like device with a tablet inside, with an upward arrow indicating to pull or push the plunger. The image is likely part of a preparation or administration guide for Everolimus tablets for suspension.*

FDA Label Image

Figure-n (Figure N)

Illustration showing a hand administering an oral suspension using a syringe into a child's mouth, depicting the proper technique for giving Everolimus tablet prepared for suspension by oral route.*

FDA Label Image

Figure-o (Figure O)

An instructional illustration showing the preparation of an Everolimus oral suspension tablet. It depicts a hand stirring a syringe in a glass of liquid, then submerging the syringe in the liquid, likely to mix or prepare the suspension for dosing.*

FDA Label Image

Figure-p (Figure P)

An instructional illustration showing a hand holding a syringe drawing liquid from a container, with an inset detail highlighting the syringe barrel marked for air volume. The image appears to demonstrate proper technique for withdrawing medication or air adjustment in an oral suspension preparation.*

FDA Label Image

Figure-q (Figure Q)

Illustration showing a hand holding a tablet-for-suspension syringe, with an arrow indicating a counterclockwise twisting or turning motion. The image likely depicts part of the preparation or administration process for Everolimus oral suspension tablets by ANI Pharmaceuticals.*

FDA Label Image

Figure-r (Figure R)

An instructional illustration showing a gloved hand holding a syringe, demonstrating the upward motion to draw liquid into the syringe. This image likely relates to preparation or administration steps for Everolimus oral suspension tablets by ANI Pharmaceuticals, Inc.*

FDA Label Image

Figure-s (Figure S)

An instructional line drawing showing the use of an oral syringe to administer liquid medication into a person's mouth. The syringe is positioned at the side of the mouth, with an arrow indicating the direction of medicine flow inside the oral cavity.*

FDA Label Image

Figure-t (Figure T)

An instructional black and white illustration showing two hands being washed under running water from a faucet. The image emphasizes proper handwashing technique with visible soap bubbles on the hands.*

FDA Label Image

Figure-u (Figure U)

An instructional illustration showing a hand pulling on a glove at the wrist, demonstrating the correct way to put on a disposable glove. The image emphasizes hand safety and hygiene practices.*

FDA Label Image

Figure-v (Figure V)

An illustration showing a medication cup filled with water up to the 25 mL mark, indicating the required amount of water to be used. The cup has measurement markings at 5 mL intervals up to 30 mL.*

FDA Label Image

Figure-w (Figure W)

An instructional illustration showing a hand wearing a glove pouring a measured liquid from a small graduated cup into a glass. The image suggests preparation or administration of an oral suspension for Everolimus tablets for suspension.*

FDA Label Image

Figure-x (Figure X)

An instructional illustration showing a person cutting an oral tablet tablet strip with scissors. The hands hold the strip and scissors to divide the tablets for dosing or preparation. No text is legible.*

FDA Label Image

Figure-y (Figure Y)

An instructional illustration showing a hand holding a tablet above a glass of water with an arrow indicating the tablet is to be dropped into the water, depicting preparation or administration steps for oral tablets.*

FDA Label Image

Figure-z (Figure Z)

Illustration showing two tablets dissolving in a glass of liquid alongside a timer indicating a 3-minute duration, suggesting a preparation or suspension step for Everolimus tablets for suspension.*

FDA Label Image

Table One (Pil 1)

A bullet-point list describing potential symptoms including fever, chills, skin rash, joint pain and swelling, tiredness, loss of appetite, nausea, pale stools or dark urine, yellowing of the skin, and pain in the upper right side of the stomach.*

FDA Label Image

Structure (Structure)

Chemical structure of Everolimus, showing its molecular arrangement with various carbon, oxygen, and nitrogen atoms connected by single and double bonds in a complex ring and chain formation.*

FDA Label Image

Table-19 (Table 19)

A data table comparing the incidence and severity of adverse events for Everolimus Tablets for Oral Suspension at target blood levels of 3-7 ng/mL and 9-15 ng/mL versus placebo. Categories include gastrointestinal, infections, general, respiratory/thoracic/mediastinal, and skin/subcutaneous tissue adverse events, with percentages shown for all grades and grades 3-4. The table includes specific events like stomatitis, diarrhea, vomiting, nasopharyngitis, pyrexia, cough, and rash with grading per NCI CTCAE Version 4.03.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.